Home/Hedge Fund Intelligence/Inhibrx Biosciences, Inc.
Nasdaq: INBXStockForm 13F30 Jun 2026

Hedge funds that hold Inhibrx Biosciences, Inc. Nasdaq: INBX

CUSIP 45720N103 · who reports it, how much, and how much it matters to them

27 of the 720 hedge fund managers we track reported shares of Inhibrx Biosciences, Inc. (Nasdaq: INBX) on Form 13F for 30 June 2026. Between them they reported USD 408m. The largest position belongs to Perceptive Advisors, at USD 123m. The manager with the most riding on it is PFM Health Sciences, where it is 2.5% of the reported book.

Managers reporting it27of 720 we track
Value they reportUSD 408mshares only, 30 Jun 2026
Funds they run331with a file on PPLI.com
Largest positionUSD 123mPerceptive Advisors
Typical weight0.0%median share of a manager's book
Heaviest weight2.5%PFM Health Sciences

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

27 managers, USD 408m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Inhibrx Biosciences, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Perceptive Advisors6 funds on PPLI.comUSD 123m1.8%
2Viking Global Investors4 funds on PPLI.comUSD 106m0.3%
3Schonfeld Strategic Advisors30 funds on PPLI.comUSD 66m0.2%
4PFM Health Sciences3 funds on PPLI.comUSD 29m2.5%
5Sofinnova Investments1 fund on PPLI.comUSD 29m1.5%
6Millennium Management6 funds on PPLI.comUSD 14m0.0%
7Renaissance Technologies13 funds on PPLI.comUSD 5.9m0.0%
8Voleon Capital Management13 funds on PPLI.comUSD 5.5m0.1%
9Voloridge Investment Management6 funds on PPLI.comUSD 4.6m0.0%
10Western Standard2 funds on PPLI.comUSD 4.5m1.5%
11Arrowmark Colorado Holdings24 funds on PPLI.comUSD 3.3m0.1%
12Empyrean Capital Partners2 funds on PPLI.comUSD 2.8m0.1%
13Atom Investors1 fund on PPLI.comUSD 2.8m0.2%
14POINT72 Asset Management17 funds on PPLI.comUSD 2.5m0.0%
15D. E. Shaw & Co.15 funds on PPLI.comUSD 2.1m0.0%
16Verition Fund Management3 funds on PPLI.comUSD 1.7m0.0%
17Marshall Wace LLP84 funds on PPLI.comUSD 834,0000.0%
18Brevan Howard Capital Management39 funds on PPLI.comUSD 725,0000.0%
19Squarepoint Ops7 funds on PPLI.comUSD 620,0000.0%
20Platinum Investment Management11 funds on PPLI.comUSD 582,0000.1%
21Cannon Global Investment Management2 funds on PPLI.comUSD 559,0001.6%
22Exoduspoint Capital Management7 funds on PPLI.comUSD 532,0000.0%
23Balyasny Asset Management25 funds on PPLI.comUSD 448,0000.0%
24Jain Global1 fund on PPLI.comUSD 312,0000.0%
25Fora Capital1 fund on PPLI.comUSD 301,0000.0%
26Nine Masts Capital1 fund on PPLI.comUSD 284,0000.0%
27Fulcrum Asset Management LLP7 funds on PPLI.comUSD 78,1190.0%
Next: where it matters most
Where it matters most

For PFM Health Sciences it is 2.5% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1PFM Health SciencesUSD 29m2.5%
2Perceptive AdvisorsUSD 123m1.8%
3Cannon Global Investment ManagementUSD 559,0001.6%
4Western StandardUSD 4.5m1.5%
5Sofinnova InvestmentsUSD 29m1.5%
6Viking Global InvestorsUSD 106m0.3%
7Atom InvestorsUSD 2.8m0.2%
8Schonfeld Strategic AdvisorsUSD 66m0.2%
9Platinum Investment ManagementUSD 582,0000.1%
10Arrowmark Colorado HoldingsUSD 3.3m0.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Inhibrx Biosciences, Inc.

What is the ticker symbol of Inhibrx Biosciences, Inc.?

Inhibrx Biosciences, Inc. trades under the symbol INBX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 45720N103.

Which hedge funds own Inhibrx Biosciences, Inc. (Nasdaq: INBX)?

27 of the 720 hedge fund managers PPLI.com tracks reported Inhibrx Biosciences, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Perceptive Advisors (USD 123m), Viking Global Investors (USD 106m), Schonfeld Strategic Advisors (USD 66m), PFM Health Sciences (USD 29m) and Sofinnova Investments (USD 29m).

How many hedge funds hold Inhibrx Biosciences, Inc.?

27 managers in our coverage reported it, and between them they run 331 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Inhibrx Biosciences, Inc.?

PFM Health Sciences, where the position was 2.5% of the reported 13F book at 30 June 2026.

Does this show who is short Inhibrx Biosciences, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Inhibrx Biosciences, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.